Skip to content

The Impact of Fospropofol Disodium versus Propofol MCT/LCT on Early Postoperative Recovery Quality (QoR-15) in Elderly Patients Undergoing Laparoscopic Gastrointestinal Tumor Resection

The Impact of Fospropofol Disodium versus Propofol MCT/LCT on Early Postoperative Recovery Quality (QoR-15) in Elderly Patients Undergoing Laparoscopic Gastrointestinal Tumor Resection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117180
Enrollment
Unknown
Registered
2026-01-20
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quality of postoperative recovery in patients undergoing gastrointestinal tumor surgery

Interventions

Group A:Anesthesia induction: Anesthesia induction in group A was induced by intravenous injection of phosphopropofenol disodium 10~20mg/kg, sufentanil 0.3µg/kg, and cis-atracurium 0.2mg/kg. Group A w
Group B:The control group did not use phosphoropofol disodium intraoperatively or in the analgesic pump

Sponsors

The Fourth Affiliated Hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age: >=65 years old, gender is not limited; (2) ASA grade II-III; (3) Laparoscopic gastrointestinal tumor surgery is proposed, with a duration of 2~4 hours; (4) BMI:18~30kg/m^2; (5) No history of drug allergy; (6) Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Severe cardiovascular and cerebrovascular diseases (such as NYHA grade >= III or LVEF =160/100 mmHg); acute coronary syndrome or stroke within 6 months); (2) Abnormal liver and kidney function (ALT/AST> 2-fold upper limit, eGFR7.5%); (4) History of neurological or psychiatric diseases; (5) Allergy to propofol or soy/egg; (6) Intraoperative blood loss greater than 15ml/kg or intraoperative blood transfusion (7) Those with broken or infected skin in the BIS monitoring area; (8) Admitted to the ICU after surgery; (9) Patients who are deemed inappropriate by the investigator to participate in this trial or the patient refuses to participate in this trial.

Design outcomes

Primary

MeasureTime frame
The QoR 15 scores of the two groups were recorded at 1 day before, 1 day and 3 days after surgery;

Secondary

MeasureTime frame
MAP, heart rate, and SpO2 5 minutes before anesthesia induction (T0), 1 minute after induction (T1), 1 minute after endotracheal intubation (T2), immediately after skin incision (T3) and immediately after endotracheal extubation (T4).;Duration of anesthesia (time from the start of anesthesia to the discontinuation of intravenous anesthetic infusion), operative time, intraoperative fluid volume, blood loss, urine output, use of anesthetic and vasoactive drugs, hypotension (MAP decrease >20% of basal value, duration =120s), and bradycardia (heart rate <50 beats/min).;Time to awakening (time from discontinuation of intravenous anesthetic infusion to awakening), time to extubation (time from discontinuation of intravenous anesthetic infusion to endotracheal extubation), length of stay in the anesthesia recovery unit (PACU) and length of hospital stay after surgery;Restlessness score (RS) score and Ramsay sedation score upon awakening;

Countries

China

Contacts

Public ContactJian zhan

The Fourth Affiliated Hospital of Southwest Medical University

1119042327@qq.com+86 135 5166 6643

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026